Survey of Ophthalmology
Volume 51, Issue 1 , Pages 19-40 , January 2006

Update on Ocular Complications of Systemic Cancer Chemotherapy

  • Katharina E. Schmid, MD

      Affiliations

    • The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Lasersurgery, Department of Ophthalmology, Rudolf Foundation Clinic Vienna, Austria
    • Corresponding Author InformationReprint address: Dr. Katharina E. Schmid, The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Lasersurgery, Department of Ophthalmology, Rudolf Foundation Clinic, Juchgasse 25, A-1030 Vienna, Austria.
    • ,
  • Gabriela V. Kornek, MD

      Affiliations

    • Division of Oncology, Department of Internal Medicine I, Vienna University Medical School, Vienna, Austria
    • ,
  • Werner Scheithauer, MD

      Affiliations

    • Division of Oncology, Department of Internal Medicine I, Vienna University Medical School, Vienna, Austria
    • ,
  • Susanne Binder, MD

      Affiliations

    • The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Lasersurgery, Department of Ophthalmology, Rudolf Foundation Clinic Vienna, Austria

References 

  1. Agarwal MR, Esmaeli B, Burnstine MA. Squamous metaplasia of the canaliculi associated with 5-fluorouracil: a clinicopathologic case report. Ophthalmology. 2002;109:2359–2361
  2. Ah-Song R, Sasco AJ. Tamoxifen and ocular toxicity. Cancer Detect Prev. 1997;21:522–531
  3. Albert DM, Wong VG, Henderson ES. Ocular complications of vincristine therapy. Arch Ophthalmol. 1967;78:709–713
  4. Alexander P. Radiation imitative chemicals. Sci Am. 1980;202:99–108
  5. Al-Tweigeri T, Nabholtz JM, Mackey JR. Ocular toxicity and cancer chemotherapy. Cancer. 1996;78:1359–1373
  6. Anderson B, Anderson B. Necrotizing uveitis incident to perfusion of intracranial malignancies with nitrogen mustard and related compounds. Trans Am Ophthalmol Soc. 1960;58:95–104
  7. Ashford AR, Donev I, Tlwarl RP. Reversible ocular toxicity related to tamoxifen therapy. Cancer. 1988;61:33–35
  8. Awidi AS. Blindness and vincristine. Ann Intern Med. 1980;93:781
  9. Becher R, Schutt P, Oleska R. Peripheral neuropathy and ophthalmologic toxicity after treatment with cis-dichlorodiamminoplatinum. J Cancer Res Clin Oncol. 1980;96:219–221
  10. Berman IJ, Mann MP. Seizures and transient cortical blindness associated with cisplatin therapy in a thirty year old man. Cancer. 1980;45:764–766
  11. Bixenman WW, Nicholls JVV, Warwick OH. Oculomotor disturbances associated with 5-fluorouracil chemotherapy. Am J Ophthalmol. 1968;83:604–608
  12. Blum JL. Xeloda in the treatment of metastatic breast cancer. Oncology. 1999;57(Suppl 1):16–20
  13. Bonadonna G, Brusamolino E, Valagussa P. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med. 1976;294:405–410
  14. Boogerd W, Moffie D, Smets LA. Early blindness and coma during intrathecal chemotherapy for meningeal carcinomatosis. Cancer. 1990;65:452–457
  15. Brink HM, Beex LV. Punctal and canalicular stenosis associated with systemic fluorouracil therapy. Doc Ophthalmol. 1995;90:1–6
  16. Broadway DC, Grierson I, O'Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol. 1994;112:1446–1454
  17. Byrd RL, Rohrbaugh TM, Raney RB. Transient cortical blindness secondary to vincristine therapy in childhood malignancies. Cancer. 1981;47:37–40
  18. Capri G, Munzone E, Tarenzi E, et al. Optic nerve disturbances: new form of paclitaxel neurotoxicity. J Natl Cancer Inst. 1994;86:1099–1101
  19. Caraceni A, Martini C, Spatti G, et al. Recovering optic neuritis during systemic cisplatin and carboplatin chemotherapy. Acta Neurol Scand. 1997;96:260–261
  20. Caruso R, Wilding G, Ballintine E, Ozols R. Cisplatin retinopathy. Invest Ophthalmol Vis Sci. 1985;26:34
  21. Choonara IA, Overend M, Balley CC. Blurring of vision due to ifosfamide. Cancer Chemother Pharmacol. 1987;20:349
  22. Christophidis N, Vadja FJE, Lucas I, et al. Excessive lacrimation associated with detectable concentrations of 5-fluorouracil in tears and plasma. Proc Aust Soc Clin Exp Pharmacol. 1977;23:56
  23. Chun HG, Leyland-Jones BR, Caryk SM, Hoth DF. Central nervous system toxicity of fludarabine phosphate. Cancer Treat Rep. 1986;70:1225–1228
  24. Cohen RJ, Cuneo RA, Crucigar MP. Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatin, vinblastine and bleomycin. J Clin Oncol. 1983;1:392–393
  25. Conley B, O'Shaughessy J, Prindiville S, et al. Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer. J Clin Oncol. 2000;18:275–283
  26. Crispino S, Pissocaro G, Solero CL. Transient left homonymous during treatment of testicular carcinoma with cisplatin, vinblastine and bleomycin. Chemoterapia. 1984;3:337–339
  27. Damascelli B, Cantu G, Mattavelli F, et al. Intra-arterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): Phase II study of patients with squamosous cell carcinoma of the head and neck and anal canal: preliminary evidence of clinical. Cancer. 2001;92:2592–2602
  28. Dimond SB, Rudolph SH, Lubicz SS. Cerebral blindness in association with cisplatin chemotherapy for advanced carcinoma of the fallopian tube. Obstet Gynecol. 1982;59:845–865
  29. Dooley M, Goa KL. Capecitabine. Drugs. 1999;58:69–76
  30. Doroshow JH, Locker GY, Gasterland DE, et al. Ocular irritation from high dose methotrexate therapy: pharmacokinetics of drug in the tear film. Cancer. 1981;48:2158–2162
  31. Eiseman AS, Flanagan JC, Brooks AB, et al. Ocular surface, ocular adnexal, and lacrimal complications associated with the use of systemic 5-fluorouracil. Ophthal Plast Reconstr Surg. 2003;19:216–224
  32. Esmaeli B, Burnstine MA, Ahmadi MA, et al. Docetaxel-induced histologic changes in the lacrimal sac and the nasal mucosa. Ophthal Plast Reconstr Surg. 2003;19:305–308
  33. Esmaeli B, Hidaji L, Adinin RB, et al. Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. Cancer. 2003;98:504–507
  34. Fety R, Rolland F, Barberi-Heyob M, et al. Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Clin Cancer Res. 1998;4:2039–2045
  35. Fishman ML, Bean SC, Cogan DG. Optic atrophy following prophylactic chemotherapy and cranial radiation for acute lymphocytic leukemia. Am J Ophthalmol. 1976;82:571–576
  36. Fortin D, Salamé JA, Desjardins A, et al. Technical modification in the intracarotid chemotherapy and osmotic blood-brain barrier disruption procedure to prevent the relapse of carboplatin-induced orbital pseudotumor. AJNR Am J Neuroradiol. 2004;25:830–834
  37. Fraunfelder FT, Meyer SM. Ocular toxicity of antineoplastic agents. Ophthalmology. 1983;90:1–3
  38. Gamelin E, Boisdron-Celle M, Delva R, et al. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J Clin Oncol. 1998;16:1470–1478
  39. Gorin MB, Day R, Costantino JP, et al. Long-term tamoxifen citrate use and potential ocular toxicity. Am J Ophthalmol. 1998;125:493–501
  40. Greenberg HS, Ensminger WD, Chandler WF, et al. Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system. J Neurosurg. 1984;61:423–429
  41. Grever MR, Siaw MF, Jacob WF, et al. The biochemical and clinical consequences of 2′-deoxycoformycin in refractory lymphoproliferative malignancy. Blood. 1981;57:406–417
  42. Grimson BS, Mahaley MS, Dubey HD, et al. Ophthalmic and central nervous system complications following intracarotid BCNU (Carmustine). J Clin Neuroophthalmol. 1981;1:261–264
  43. Hansson HA. Retinal changes induced by treatment with vincristine and vinblastine. Doc Ophthalmol. 1972;31:65–88
  44. Hilliard LM, Berkow RL, Watterson J, et al. Retinal toxicity associated with cisplatin and etoposide in pediatric patients. Med Pediatr Oncol. 1997;28:310–313
  45. Hopen G, Mondino BJ, Johnson BL, et al. Corneal toxicity with systemic cytarabine. Am J Ophthalmol. 1981;91:500–504
  46. Imperia PS, Lazarus HM, Lass JH. Ocular complications of systemic cancer chemotherapy. Surv Ophthalmol. 1989;34:209–230
  47. Itoh M, Aoyama T, Yamamura Y, et al. Effects of the rational use of corticosteroids eye drops for the prevention of ocular toxicity in high-dose cytosine arabinoside therapy. Yakugaku Zasshi. 1999;119:229–235
  48. Jack MK, Hicks JD. Ocular complications in high-dose chemoradiotherapy and marrow transplantation. Ann Ophthalmol. 1981;13:709–711
  49. Jansman FG, Sleijfer DT, de Graaf JC, et al. Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer. Drug Saf. 2001;24:353–367
  50. Johnson DW, Cagnoni PJ, Schossau TM, et al. Optic disc and retinal microvasculopathy after high-dose chemotherapy and autologous hematopoietic progenitor cell support. Bone Marrow Transplant. 1999;24:785–792
  51. Kaida T, Ogawa T, Amemiya T. Cataract induced by short-term administration of large doses of busulfan: a case report. Ophthalmologica. 1999;213:397–399
  52. Kaiser-Kupfer MI, Kupfer C, Rodrigues MM. Tamoxifen retinopathy. A clinicopathologic report. Ophthalmology. 1981;88:89–93
  53. Kaiser-Kupfer MI, Lippman ME. Tamoxifen retinopathy. Cancer Treat Rep. 1978;62:315–320
  54. Katz BJ, Ward JH, Digre KB, et al. Persistent severe visual and electroretinographic abnormalities after intravenous Cisplatin therapy. J Neuroophthalmol. 2003;23:132–135
  55. Kefford RF, Fox RM. Deoxycoformycin-induced response in chronic lymphocytic leukaemia: deoxyadenosine toxicity in non-replicating lymphocytes. Br J Haematol. 1982;50:627–636
  56. Kende G, Sirkin SR, Thomas PR, et al. Blurring of vision: a previously undescribed complication of cyclophosphamide therapy. Cancer. 1979;44:69–71
  57. Khaw PT, Sherwood MB, MacKay SL, et al. Five-minute treatments with fluorouracil, floxuridine, and mitomycin have long-term effects on human Tenon's capsule fibroblasts. Arch Ophthalmol. 1992;110:1150–1154
  58. Kraut EH, Bouroncle BA, Grever MR. Pentostatin in the treatment of advanced hairy cell leukemia. J Clin Oncol. 1989;7:168–172
  59. Lass JH, Lazarus HM, Reed MD, et al. Topical corticosteroid therapy for corneal toxicity from systemically administered cytarabine. Am J Ophthalmol. 1982;94:617–621
  60. Lauer AK, Wobig JL, Shults WT, et al. Severe ocular and orbital toxicity after intracarotid etoposide phosphate and carboplatin therapy. Am J Ophthalmol. 1999;127:230–233
  61. Lazzaroni F, Scorolli L, Pizzoleo CF, et al. Tamoxifen retinopathy: does it really exist?. Graefes Arch Clin Exp Ophthalmol. 1998;236:669–673
  62. Lee V, Bentley CR, Olver JM. Sclerosing canaliculitis after 5-fluorouracil breast cancer chemotherapy. Eye. 1998;12(Pt 3a):343–349
  63. Loprinzi CL, Wender DB, Veeder MH, et al. Inhibition of 5-fluorouracil-induced ocular irritation by ocular ice packs. Cancer. 1994;74:945–948
  64. Maeda Y, Nishida M, Takao T, et al. A case of multiple liver metastases from breast cancer successfully treated with intra-arterial administration of docetaxel. Gan To Kagaku Ryoho. 1999;26:1051–1054
  65. Major PP, Agarwal RP, Kufe DW. Clinical pharmacology of deoxycoformycin. Blood. 1981;58:91–96
  66. Margileth DA, Poplack DG, Pizzo PA, et al. Blindness during remission in two patients with acute lymphoblastic leukemia: a possible complication of multimodality therapy. Cancer. 1977;39:58–61
  67. Margo CE, Murtagh FR. Ocular and orbital toxicity after intracarotid cisplatin therapy. Am J Ophthalmol. 1993;116:508–509
  68. McKeown CA, Swartz M, Blom J, et al. Tamoxifen retinopathy. Br J Ophthalmol. 1981;65:177–179
  69. Millay RH, Klein ML, Shults WT, et al. Maculopathy associated with combination chemotherapy and osmotic opening of the blood-brain barrier. Am J Ophthalmol. 1986;102:626–632
  70. Miller DF, Bay JW, Lederman RJ, et al. Ocular and orbital toxicity following intracarotid injection of BCNU (carmustine) and cisplatinum for malignant gliomas. Ophthalmology. 1985;92:402–406
  71. Mulvihill A, Budning A, Jay V, et al. Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma. Arch Ophthalmol. 2003;121:1120–1124
  72. Nayfield SG, Karp JE, Ford LG, et al. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst. 1991;83:1450–1459
  73. Norton SW, Stockman JA. Unilateral optic neuropathy following vincristine chemotherapy. J Pediatr Ophthalmol Strabismus. 1979;16:190–193
  74. O'Brien ME, Tonge K, Blake P, et al. Blindness associated with high-dose carboplatin. Lancet. 1992;339:558
  75. O'Dwyer PJ, Wagner B, Leyland-Jones B, et al. 2′-Deoxycoformycin (pentostatin) for lymphoid malignancies. Rational development of an active new drug. Ann Intern Med. 1988;108:733–743
  76. Ostrow S, Hahn D, Wiernik PH, et al. Ophthalmologic toxicity after cis-dichlorodiammineplatinum(II) therapy. Cancer Treat Rep. 1978;62:1591–1594
  77. Oura S, Sakurai T, Yoshimura G, et al. Recurrent squamosous-cell lung cancer treated with bronchial-arterial infusion of docetaxel. Case Report. Gan To Kagaku Ryoho. 1998;25:2109–2113
  78. Paganini-Hill A, Clark LJ. Eye problems in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat. 2000;60:167–172
  79. Pavlidis NA, Petris C, Briassoulis E, et al. Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients. Cancer. 1992;69:2961–2964
  80. Percy DH, Danylchuk KD. Experimental retinal dysplasia due to cytosine arabinoside. Invest Ophthalmol Vis Sci. 1977;16:353–364
  81. Pippitt CH, Muss HB, Homesley HD, et al. Cisplatin-associated cortical blindness. Gynecol Oncol. 1981;12:253–255
  82. Ponjavic V, Gränse L, Stigmar EB, et al. Reduced full-field electroretinogram (ERG) in a patient treated with methotrexate. Acta Ophthalmol Scand. 2004;82:96–99
  83. Prasad S, Kamath GG, Phillips RP. Lacrimal canalicular stenosis associated with systemic 5-fluorouacil therapy. Acta Ophthalmol Scand. 2000;78:110–113
  84. Prim MP, de Diego JI, de Sarriá MJ, et al. [Vestibular and oculomotor changes in subjects treated with cisplatin]. Acta Otorrinolaringol Esp. 2001;52:367–370
  85. Rahl AHS, Hungerford JL, Ahmed AI. Ocular toxicity of desferrioxamine: light microscopic histochemical and ultrastructural findings. Br J Ophthalmol. 1988;70:373–381
  86. Rankin EM, Pitts JF. Ophthalmic toxicity during carboplatin therapy. Ann Oncol. 1993;4:337–338
  87. Ripps H, Carr RE, Siegel IM, et al. Functional abnormalities in vincristine-induced night blindness. Invest Ophthalmol Vis Sci. 1984;25:787–794
  88. Ritch PS, Hansen RM, Heuer DK. Ocular toxicity from high-dose cytosine arabinoside. Cancer. 1983;51:430–432
  89. Rubenstein RA, Yanoff M, Albert DM. Thrombocytopenia, anemia, and retinal hemorrhage. Am J Ophthalmol. 1968;65:435–439
  90. Rubin P, Hulette C, Khawly JA, et al. Ocular toxicity following high dose chemotherapy and autologous transplant. Bone Marrow Transplant. 1996;18:253–256
  91. Sanderson PA, Kuwabara T, Cogan DG. Optic neuropathy presumably caused by vincristine therapy. Am J Ophthalmol. 1976;81:146–150
  92. Sandler SG, Tobin W, Henderson ES. Vincristine-induced neuropathy. A clinical study of fifty leukemic patients. Neurology. 1969;19:367–374
  93. Santini J, Milano G, Thyss A, et al. 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer. 1989;59:287–290
  94. Sato Y, Morita M, Takahashi HO, et al. Combined surgery, radiotherapy, and regional chemotherapy in carcinoma of the paranasal sinuses. Cancer. 1970;25:571–579
  95. Schacter L. Etoposide phosphate: what, why, where and how?. Semin Oncol. 1996;23:1–7
  96. Schmid KE, Kornek GV, Schüll B, et al. Second-line treatment of advanced gastric cancer with oxaliplatin plus raltitrexed. Onkologie. 2003;26:255–258
  97. Seidman AD, Barrett S, Canezo S. Photopsia during 3-hour paclitaxel administration at doses > or = 250 mg/m2. J Clin Oncol. 1994;12:1741–1742
  98. Shapiro MS, Thoft RA, Friend J, et al. 5-fluorouracil toxicity to the ocular surface epithelium. Invest Ophthalmol Vis Sci. 1985;26:580–583
  99. Shingleton BJ, Bienfang DC, Albert DM, et al. Ocular toxicity associated with high-dose carmustine. Arch Ophthalmol. 1982;100:1766–1772
  100. Shurin SB, Rekate HL, Annable W. Optic atrophy induced by vincristine. Pediatrics. 1982;70:288–291
  101. Skolnick CA, Doughman DJ. Erosive conjunctivitis and punctal stenosis secondary to docetaxel (taxotere). Eye Contact Lens. 2003;29:134–135
  102. Sommer S, Badet JC, Zaoui M, et al. [Birdshot chorioretinopathy associated with tamoxifen retinal toxicity]. J Fr Ophtalmol. 2000;23:494–497
  103. Spiers AS, Ruckdeschel JC, Horton J. Effectiveness of pentostatin (2′-deoxycoformycin) in refractory lymphoid neoplasms. Scand J Haematol. 1984;32:130–134
  104. Stentoft J. The toxicity of cytarabine. Drug Saf. 1990;5:7–27
  105. Stern WH, Guerin CJ, Erickson PA, et al. Ocular toxicity of fluorouracil after vitrectomy. Am J Ophthalmol. 1983;96:43–51
  106. Stevens A, Spooner D. Lacrimal duct stenosis and other ocular toxicity associated with adjuvant cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy for early stage breast cancer. Clin Oncol (R Coll Radiol). 2001;13:438–440
  107. Stewart DJ, Wallace S, Feun L, et al. A phase I study of intracarotid artery infusion of cis-Diamminedichloroplatinum(II) in patients with recurrent malignant intracerebral tumors. Cancer Res. 1982;42:2059–2062
  108. Sullivan RD. The treatment of human cancer with intraarterial nitrogen mustard. Cancer. 1951;6:121–131
  109. Tang R, Shields J, Schiffman J, et al. Retinal changes associated with tamoxifen treatment for breast cancer. Eye. 1997;11:295–297
  110. Toker E, Yenice O, Ogˇüt MS. Isolated abducens nerve palsy induced by vincristine therapy. J AAPOS. 2004;8:69–71
  111. Urba S, Forastiere AA. Retrobulbar neuritis in a patient treated with intraarterial cisplatin for head and neck cancer. Cancer. 1988;62:2094–2097
  112. Van Cutsem E, Peeters M, Verslype C, et al. The medical treatment of colorectal cancer: actual status and new developments. Hepatogastroenterology. 1999;46:709–716
  113. Vizel M, Oster MW. Ocular side effects of cancer chemotherapy. Cancer. 1982;49:1999–2002
  114. Voest EE, Neijt JP, Keunen JE, et al. Phase I study using desferrioxamine and iron sorbitol citrate in an attempt to modulate the iron status of tumor cells to enhance doxorubicin activity. Cancer Chemother Pharmacol. 1993;31:357–362
  115. Vogler WR, Winton EF, Heffner LT, et al. Ophthalmological and other toxicities related to cytosine arabinoside and total body irradiation as preparative regimen for bone marrow transplantation. Bone Marrow Transplant. 1990;6:405–409
  116. Waikhom B, Fraunfelder FT, Henner WD, et al. Severe ocular irritation and corneal deposits associated with capecitabine use. N Engl J Med. 2000;343:740–741
  117. Walsh TJ, Clark AW, Parhad IM, et al. Neurotoxic effects of cisplatin therapy. Arch Neurol. 1982;39:719–720
  118. Wang MY, Arnold AC, Vinters HV, et al. Bilateral blindness and lumbosacral myelopathy associated with high-dose carmustine and cisplatin therapy. Am J Ophthalmol. 2000;130:367–368
  119. Watanabe W, Kuwabara R, Nakahara T, et al. Severe ocular and orbital toxicity after intracarotid injection of carboplatin for recurrent glioblastomas. Graefes Arch Clin Exp Ophthalmol. 2002;240:1033–1035
  120. Wilding G, Caruso R, Lawrence TS, et al. Retinal toxicity after high-dose cisplatin therapy. J Clin Oncol. 1985;3:1683–1689
  121. Wilson RH, Lehky T, Thomas RR, et al. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol. 2002;20:1767–1774
  122. Wu HM, Lee AG, Lehane DE, et al. Ocular and orbital complications of intraarterial cisplatin. A case report. J Neuroophthalmol. 1997;17:195–198
  123. Yanyali AC, Freund KB, Sorenson JA, et al. Tamoxifen retinopathy in a male patient. Am J Ophthalmol. 2001;131:386–387

 The authors reported no proprietary or commercial interest in any product mentioned or concept discussed in this article.

PII: S0039-6257(05)00192-X

doi: 10.1016/j.survophthal.2005.11.001

Survey of Ophthalmology
Volume 51, Issue 1 , Pages 19-40 , January 2006

Article Tools

* Image Usage & Resolution